The U.S. Food and Drug Administration (FDA) said it found adulteration and “significant violations” of current good manufacturing practice (CGMP) regulations at Strides Pharma Sciences Ltd’s plant in Puducherry in south India.
U.S. FDA finds 'significant violations' at India's Strides plant